Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Edwards Lifesciences loses TAVR leader to robotics firm, announces replacement
The change comes at a momentous time for the company's TAVR portfolio, which made history in May by receiving the very first FDA approval for treating asymptomatic severe AS.
Q&A: What Medicare covering TriClip means for heart patients with leaky tricuspid valves
The tricuspid valve has been at the center of several key policy shifts in recent years. In fact, Medicare now covers both T-TEER and TTVR when performed with FDA-approved devices. We spoke to interventional cardiologist Jason H. Rogers, MD, to learn more about how this momentum has impacted patient care.
How pairing SAVR with additional heart surgeries affects mortality risk
When older patients undergo SAVR with concomitant procedures, it increases their short- and long-term risks of mortality. Should this influence care teams to consider more transcatheter treatments?
New device could make it easier than ever for cardiologists to perform BASILICA before TAVR
Toby Rogers, MD, PhD, noted that BASILICA is a fairly complex procedure. Using this advanced technology, however, could make it easier to perform and improve patient access.
Stroke risk after TAVR still much higher for female patients
Women are associated with a significantly higher rate of in-hospital disabling strokes than men, according to a new study of nearly 380,000 TAVR patients. What can cardiologists do to help limit these complications?

Edwards Lifesciences loses TAVR leader to robotics firm, announces replacement

The change comes at a momentous time for the company's TAVR portfolio, which made history in May by receiving the very first FDA approval for treating asymptomatic severe AS.

cardiologist Jason H. Rogers, MD, a professor at UC Davis Medical Center in Sacramento, California

Q&A: What Medicare covering TriClip means for heart patients with leaky tricuspid valves

The tricuspid valve has been at the center of several key policy shifts in recent years. In fact, Medicare now covers both T-TEER and TTVR when performed with FDA-approved devices. We spoke to interventional cardiologist Jason H. Rogers, MD, to learn more about how this momentum has impacted patient care.

How pairing SAVR with additional heart surgeries affects mortality risk

When older patients undergo SAVR with concomitant procedures, it increases their short- and long-term risks of mortality. Should this influence care teams to consider more transcatheter treatments?

Toby Rogers, MD, Medstar, discusses a new dedicated device for BASILICA used in TAVR.

New device could make it easier than ever for cardiologists to perform BASILICA before TAVR

Toby Rogers, MD, PhD, noted that BASILICA is a fairly complex procedure. Using this advanced technology, however, could make it easier to perform and improve patient access.

stroke brain dementia alzheimer's puzzle mental health

Stroke risk after TAVR still much higher for female patients

Women are associated with a significantly higher rate of in-hospital disabling strokes than men, according to a new study of nearly 380,000 TAVR patients. What can cardiologists do to help limit these complications?

First patient treated with BASILICA before valve-in-valve TAVR in a mechanically-expanded valve

A heart team chose to perform BASILICA before valve-in-valve TAVR in a failed Lotus device to help minimize the risk of complications. These scenarios will likely grow more and more common as patients outlive their TAVR valves.

FDA clears AI-powered software for real-time TAVR guidance

Caranx Medical is focused on using AI, robotics and other advanced technologies to expand patient access to life-saving procedures. This new software, for example, helps guide cardiologists through complex TAVR procedures.

The balloon-expandable Myval transcatheter aortic valve replacement (TAVR) valve is associated with positive real-world data after four years.

Myval TAVR valve associated with positive durability data after 4 years

Researchers have been spending more and more time evaluating the Myval TAVR valve from Indian medtech company Meril Life Sciences. The balloon-expandable device is available in some parts of the world, but not the United States.